Table 2.
Efficacy results in colorectal (HT-29, HCT116) and lung (NCI-H460, A549) models treated with IT-141 or IT-147.
| Tumor | Treatment | % TGI | Fold Change |
|---|---|---|---|
| Formulation Control | - | 4.8 | |
| HT-29 | IT-141 (40 mg/kg) | 64% | 2.4 |
| IT-141 (60 mg/kg) | 98% | 1.1 | |
|
| |||
| Formulation Control | - | 9.7 | |
| HCT116 | Irinotecan | 70% | 3.6 |
| IT-141 (50 mg/kg) | 106% | 0.5 | |
|
| |||
| Formulation Control | - | 11.0 | |
| NCI-H460 | Epothilone D | 23% | 8.8 |
| IT-147 (30 mg/kg) | 40% | 7.1 | |
|
| |||
| Formulation Control | - | 2.2 | |
| A549 | Epothilone D | 2% | 2.2 |
| IT-147 (30 mg/kg) | 46% | 1.6 | |
|
| |||
| Formulation Control | - | 8.6 | |
| HCT116 | Epothilone D | 38% | 5.7 |
| IT-147 (30 mg/kg) | 87% | 2.0 | |